交易中 09-04 09:47:06 美东时间
0.000
0.00%
Apogee Therapeutics reported positive 16-week Phase 2 Part A data for APG777, a potentially best-in-class anti-IL-13 antibody for moderate-to-severe atopic dermatitis (AD). The drug met all primary and key secondary endpoints, demonstrating significant efficacy and reduced injection burden for patients, potentially requiring 2-4 injections per year versus 26 for current treatments. Part B of the APEX trial is on track for a mid-2026 readout, with...
08-11 11:00